Patent ID: 7842676

Claim:
A method to treat an advanced solid cancer in a human subject, said method comprising administering to said subject a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of irinotecan and floxuridine, wherein said fixed, non-antagonistic molar ratio is maintained in the plasma for at least about 4 hours, wherein said fixed, non-antagonistic molar ratio of irinotecan and floxuridine is about 1:1 and is encapsulated in liposomes, wherein each dose of the composition is administered intravenously to said human subject over a period of 30 minutes to three hours, wherein the dose contains less than 0.0004 moles/m 2 of floxuridine, and wherein floxuridine is administered at a level not greater than 0.0008 moles/m 2 /month, and wherein said advanced solid cancer is a gastric cancer, a renal cancer, a breast cancer, a colon cancer, an esophageal cancer, a prostate cancer, a pancreatic cancer, an ovarian cancer, an osteosarcoma, or a sphenoid sinus cancer.